Team

Shyh-Han Tan, Ph.D.

Dr. Tan earned his B.Sc. and Ph.D. from the National University of Singapore, where his doctoral research focused on the transcriptional regulation of Human Papillomavirus type-16 under Dr. Hans-Ulrich Bernard. He completed his postdoctoral training with Dr. Mary Dasso at NICHD, NIH, characterizing the role of SUMO isopeptidase SUSP1 in nuclear body formation. He transitioned to prostate cancer research with Dr. Marja Nevalainen at Georgetown University and later at Thomas Jefferson University.  

Dr. Tan’s earlier work demonstrated that ERG inhibits prostate epithelial cell differentiation and promotes EMT by repressing ANXA2 transcription. His findings highlighted a reciprocal correlation between ERG and ANXA2 expression in prostate tumors, suggesting ANXA2’s potential as a prognostic marker. He also led the development of a specific ERG monoclonal antibody, simplifying the detection of TMPRSS2-ERG fusion in prostate cancer by IHC. This antibody has been instrumental in studying the clonal progression of ERG-positive tumors and stratifying prostate cancers by ERG status.

Kevin Guan, Graduate Student

Kevin Guan earned his bachelors in Biomolecular Sciences with a concentration in Biotechnology from New York University Tandon School of Engineering. He is currently doing a PhD in Molecular and Cellular Biology at the Uniformed Services University. His dissertation work uses machine learning to better diagnose and study prostate cancer. Kevin Guan hopes to advance medicine by using the latest breakthroughs in AI, ML, and DL to solve some of cancer medicine's most pressing issues.